Bone morphogenetic protein 2 gene transduction enhances the osteogenic potential of human urine-derived stem cells by Junjie Guan et al.
Guan et al. Stem Cell Research & Therapy 2015, 6:5
http://stemcellres.com/content/6/1/5RESEARCH Open AccessBone morphogenetic protein 2 gene transduction
enhances the osteogenic potential of human
urine-derived stem cells
Junjie Guan1†, Jieyuan Zhang1†, Zhenzhong Zhu1, Xin Niu2, Shangchun Guo2, Yang Wang1,2*
and Changqing Zhang1,2*Abstract
Introduction: Urine-derived stem cells (USCs) have the ability to differentiate into osteogenic lineage. Previous
studies have raised the possibility that USCs could be used for bone repair. To harness the power of USCs in
promoting bone regeneration, methods must be developed to induce USCs to osteogenic lineage efficiently. The
present study investigates the effect of lentivirus-encoded bone morphogenetic protein 2 (BMP2) gene transduction
on the osteogenic potential of USCs.
Methods: USCs were isolated from voided urine and transduced with Lentiviral vector encoding BMP2. An in vitro
study was performed to detect Lentiviral-BMP2 transduced USCs differentiated towards osteogenic lineage. Furthermore,
Lentiviral-BMP2 transduced USCs were transplanted in vivo to examine the ectopic bone formation ability. After six
weeks, retrieval samples were obtained for immunostaining and histological analysis.
Results: The results showed that the transduction efficiencies were over 90%, and transduced USCs had high
expression levels of the BMP2 gene and secreted BMP2 protein. Alkaline activity and mineral deposition staining
demonstrated that transduced USCs differentiate into osteogenic lineages without the addition of osteogenic
supplements. Transduced USCs also showed high expression of bone-related markers, including runt-related
protein-2 (Runx2) and osteocalcin (OCN), confirming this lentiviral-BMP2 construct provides sufficient stimuli for
osteogenic differentiation. Histological analysis indicated that the transduced USCs induced robust new bone
formation in nude mice. Six weeks after transplantation, human derived cells were observed to participate in
bone formation.
Conclusions: These results demonstrate that BMP2 gene transduction provides an effective method to enhance
the osteogenic potential of USCs.Introduction
Urine has recently been determined to be a source of
adult stem cells. Zhang et al. reported that urine-derived
stem cells (USCs) can be expanded in vitro and differen-
tiated into multiple cell lineages [1]. Our previous stud-
ies demonstrated that USCs express similar surface
markers as adipose-derived stem cells (ASCs). Under
certain induction conditions, USCs can differentiate* Correspondence: wang63cn@126.com; zhangcq@sjtu.edu.cn
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unless otherwise stated.into osteoblasts, chondrocytes and adipocytes [2]. Com-
pared with other cell sources, urine is vastly available
and can be obtained by non-invasive methods. The poten-
tial for USCs-based cytotherapy has gained the attention
of researchers. USCs seeded onto bacterial cellulose could
express urothelial markers [3]. USCs with a small intes-
tinal submucosal scaffold could form tissue that is similar
to the native urethral structure [4]. Those results demon-
strated that USCs hold promise for use in urinary con-
struction. We first combined USCs and a β-tricalcium
phosphate (β-TCP) scaffold to heal critically sized bone
defects in rats (data unpublished). The results showed that
USCs hold tremendous promise for bone tissue engineer-
ing; however, there is considerable room to enhance theirhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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osteogenic potential of USCs may be to transduce them so
that they express growth factors that direct USCs differenti-
ation toward the osteoblasts cell fate. Bone morphogenetic
protein 2 (BMP2), an essential growth factor for bone
formation, is a possible candidate for this application.
BMP2 belongs to the transforming growth factor beta
superfamily and has been used in spinal fusions, long
bone defects and non-union bone fractures [5]. How-
ever, human trials have been less successful than animal
studies. Researchers have found that the low biological
activity and short in vivo half-life of BMP2 may cause
this reduced success [6]. In addition, recombinant BMP2
protein is quite expensive and would represent an in-
creased health cost for treatment [7]. Therefore, re-
searchers have turned to gene therapy as an approach
to deliver therapeutic proteins in a more persistent and
physiological manner. ASCs can be transduced with
the BMP2 gene to form bone in vivo [8]. Wright et al.
transduced a retrovirus encoding BMP2 into muscle-
derived stem cells (MDSCs), and their results demon-
strated that MDSCs undergo osteogenic differentiation.
Furthermore, the transduced MDSCs induce significant
new bone formation [9]. Currently, it is still unknown
whether BMP2 gene transduction can improve the osteo-
genic ability of USCs.
The aims of present study were to: (1) determine if
human USCs can be efficiently transduced with a lentivirus
encoding BMP2; (2) determine if these transfected cells can
undergo osteogenic differentiation; and (3) determine if
transduced USCs can be used to form bone in vivo.
Methods
Isolation of human USCs
Primary USCs were harvested from five healthy adult
donors (male, age range 23 to 30 years) using methods
described previously [2]. The Ethics Committee of Shanghai
Six People’s Hospital approved the use of human urine.
All volunteers signed the informed consent. A total of
200 ml sterile urine samples were centrifuged and washed
with 80 ml phosphate-buffered saline (PBS), and cell pel-
lets were resuspended and plated in 24-well plates with
mixed culture medium. The medium included (Dulbecco’s)
modified Eagle’s medium ((D)MEM) culture medium sup-
plemented with 2% (vol/vol) fetal bovine serum (FBS)
(Gibco, Invitrogen, Grand Island, NY, USA), 10 ng/ml hu-
man epidermal growth factor (hEGF, Peprotech, NJ, USA),
2 ng/ml platelet-derived growth factor (PDGF, Millipore,
MA, USA), 1 ng/ml transforming growth factor-β (TGF-β,
Peprotech), 2 ng/ml basic fibroblast growth factor (bFGF,
Sigma-Aldrich, St. Louis, MO, USA), 0.5 μM cortisol
(Sigma-Aldrich), 25 μg/ml insulin (Humulin, Eli Lilly,
Indianapolis, USA), 20 μg/ml transferrin, 549 ng/ml adren-
aline, 50 ng/ml triiodothyronine, L-glutamine and antibiotics.Five to seven days later, the non-adherent cells were washed
out using PBS. Medium was changed every three days.
After reaching subconfluence, the cells were passaged using
trypsin.
Characterization of USCs
Surface marker expression of the USCs
To detect the surface antigens expressed on USCs, the
cells were subjected to flow cytometry analysis. Briefly,
USCs were harvested, washed and incubated with the
following fluorochrome-conjugated antibodies: CD29,
CD34, CD44, CD45, CD73, CD90, CD133 and HLA-DR
for 30 minutes at 4°C (all from BD, Biosciences, CA, USA).
The negative control received an equivalent amount of
isotype-matched antibodies. Flow cytometry was performed
using a Guava Technologies flow cytometer (Guava, Easy
Cyte HT,MA, USA). The data were analyzed using Cytosofe
(Version 5.2, Guava Technologies).
Multilineage differentiation potential
USCs were seeded onto six-well plates. The osteogenic
medium (Invitrogen, Gibco) was added when cells reached
90% confluence and the medium was replaced twice a week.
After 21 days of osteogenic differentiation, calcium depo-
sition was detected by Alizarin Red S staining. To induce
adipogenic differentiation, adipogenic medium was added
when cells reached 90% confluence (Invitrogen, Gibco), and
the medium was replaced twice a week. Intracellular lipid
droplets were confirmed by Oil Red O staining.
Construction of the lentiviral vector
Lentiviral vectors carrying human BMP2 and green
fluorescent protein (GFP) were constructed. One vector
encoded BMP2 and GFP. However, the second vector
only encoded GFP. Total RNA was harvested using the
PrimeScript RT reagent kit according to the manufac-
turer’s instructions (TAKARA-BIO, Shiga, Japan). The
RNA was converted into complementary DNA (cDNA)
using a Reverse Transcription System Kit (Invitrogen,
Carlsbad, CA, USA). Based on the cDNA sequences of
BMP2 from the Genebank database (Gen-Bank, Accession
No.NM001200), the primers were synthesized using Primer
Premier 5.0. software. The BMP2 gene was amplified by
PCR and inserted into the LV5 vector (GenePharma Co.,
Ltd, Shanghai, China). The Cytomegalovirus (CMV) pro-
moter was used to drive gene expression. The shuttle vec-
tor and packaging plasmids pGag/Pol, pRev and pVSV-G
were transfected into 293 T cells for lentiviral production.
The viruses were collected on Day 3 after the transfection
and were concentrated by ultracentrifugation.
Gene transduction
USCs were trypsinized, centrifuged and counted when
they reached 70% confluence. They were exposed to
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and 100. A total of 8 μg/ml Polybrene (Sigma) was added
to enhance the transduction efficiency. The transduction
medium was replaced with basal medium after 48 hours.
Gene transduction efficiency and cell viability assay
Cells were observed under a fluorescence microscope
three days after transduction (Nikon, ECLIPSE, Ti).
The gene transduction efficiency was further analyzed
using flow cytometry (Guava, easy Cyte HT). The cells
were trypsinized and centrifuged before analysis. Then
cells were subjected to flow cytometry (Guava easyCyte™).
The percentage of GFP-positive cells was analyzed using
Cytosofe (Version 5.2, Guava Technologies).
Cell viability was evaluated using a CCK-8 assay kit ac-
cording to the manufacturer’s instructions. In brief, 5,000
cells were plated on a 96-well assay plate containing 100 μL
culture medium. At 1, 3 and 7 days after plating, 10 μL
CCK-8 solution was added, and the plate was incubated for
two hours at 37°C in a humidified, 5% carbon dioxide atmos-
phere. The absorbance at 450 nm was then recorded using a
microplate reader (iMark™; Bio-Rad, Hercules, CA, USA).
Quantitative RT-PCR analysis
Quantitative RT-PCR was performed to detect the related
genes expression in Lentiviral-BMP2 transduced USCs at
3, 7 and 14 days after transduction. Total RNA was iso-
lated from the cells using the Trizol method (Invitrogen).
After the reverse transcription reaction, quantitative real-
time PCR was carried out using TaqMan Universal PCR
Master Mix (Roche, Branchburg, NJ, USA). The product
was quantified using a standard curve, and GAPDH was
used as control. The sequences for the primers used are
listed in Table 1. Normal USCs and Lentiviral-GFP trans-
duced USCs were analyzed as control. Each assay was per-
formed in triplicate.
BMP2 ELISA
The secretion of BMP2 was measured in the culture
medium of normal USCs, Lentiviral-GFP transducedTable 1 Primers used in RT-PCR and production sizes








Reverse GAGTCCTTCCACGATACCAUSCs and Lentiviral-BMP2 transduced USCs. Briefly,
the cells were trypsinized and seeded at a density 1 ×
105 cells/well in six-well plates. Culture medium was
collected and underwent analysis according to manufac-
turer’s instruction (Quantikine, R&D Systems, Minneapolis,
MN, USA). The protein content was determined with a
BCA protein assay kit (Pierce Biotechnolog, Rockford, IL,
USA). All experiments were performed in triplicate.
Osteogenic differentiation of Lentiviral-BMP2 transduced
USCs
To investigate the effect of inductive osteogenesis by
gene transfection only, lentiviral-BMP2 transduced USCs
were cultured in basal medium as described in the Section
‘Isolation of human USCs’. The medium was replaced
every three to four days. Osteogenic differentiation was
assessed by measuring alkaline phosphatase (ALP) activity,
mineral calcium deposition, and gene and protein expres-
sion of bone-relate markers.
Alkaline Phosphatase activity
On days 7 and 14, cells were washed twice with PBS and
then 0.1% Triton X-100 was added to dissolve the cells. The
solution was transferred into a 1.5 mL tube, and the sam-
ples were then centrifuged at 14,000 rpm at 4°C for 20 mi-
nutes. The supernatants were transferred to fresh 1.5 mL
tubes and ALP reaction buffer (100 μl 1 M Tris–HCl, 20 μl
5 mM MgCl2, and 20 μl 5 mM p-nitrophenyl phosphate)
was added. After incubation for 30 minutes at 37°C the re-
action was stopped by the addition of 50 μL of 1 N NaOH.
Using p-nitrophenol as a standard, the absorbance was
measured at 410 nm with a spectrophotometer. The ALP
activity was expressed as the value of the p-nitrophenol pro-
duction quantity divided by the reaction time and the pro-
tein synthesis quantity, as measured by a BCA Protein
assay kit (Thermo Scientific, Rockford, IL, USA).
Mineral calcium deposition
After 14 days of incubation, calcium deposition was de-
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paraformaldehyde (PFA) for 20 minutes. The fixed cells
were then washed with PBS. For the Alizarin red S stain-
ing, the cells were treated with 2% Alizarin Red S for
15 minutes at room temperature. After the removal of
unincorporated dye with distilled water, the cells were
observed under a microscope. For the von Kossa stain-
ing, cells were fixed in cold methanol for 20 minutes.
After washing with PBS, the cells were incubated with
5% silver nitrate solution under UV light for 30 minutes.
The cells were washed with PBS and treated with a 5%
solution of sodium thiosulfate (Sigma-Aldrich, St. Louis,
MO, USA). The mineralized nodules were labeled as
black spots.
Gene and protein expression of osteogenic markers OCN
and Runx2
The effect of BMP2 gene transduction on the gene expres-
sion of bone-related markers Runx2 and OCN was mea-
sured by RT-PCR. RT-PCR was performed as described
before in ‘Quantitative RT-PCR analysis’.
After 7 and 21 days of culture, cells were washed in PBS
and fixed with 4% PFA in PBS at room temperature for
15 minutes. After that, the samples were rinsed in PBS
and permeabilized in 0.1% Triton X-100 for 10 minutes.
Non-specific antigen binding was blocked with 3% BSA/
PBS at 37°C for 20 minutes. Subsequently, the cells were
incubated with primary antibody against Runx2 (Abcam,
Cambridge, UK, ab76956, 1:200) and OCN (Abcam, Cam-
bridge, UK, ab13420, 1:200) overnight at 4°C. After washing
with PBS, the cells were incubated with Alexa Fluor 594
goat anti-mouse secondary antibody (Invitrogen, 1:200) for
two hours at 37°C. Finally, the nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI), and the image was ana-
lyzed with a fluorescence microscope.
USCs transplantation and in vivo bone formation
All procedures were approved by the Shanghai Sixth
People’s Hospital Committee on the Use and Care of
Animals. USCs and Lentirival-BMP2 transduced USCs
were seeded onto a β-TCP scaffold. Two muscle pockets
were made and two different implants were placed on
each mouse. Twelve implants were placed and six mice
were needed for the whole in vivo experiments. Trans-
plantation surgery was performed as described previously
[7]. Briefly, nude mice were adequately anesthetized with
10% chloral hydrate (0.35 to 0.4 mL/100 g). A skin inci-
sion was made on the right hindlimbs, and muscle pockets
were formed by blunt dissection. The composite was im-
planted into the musculature, and the incisions were
closed with 4–0 silk suture. Animals were allowed activity
ad libitum.
Six weeks after implantation, the transplants were har-
vested from muscles, fixed in 10% formalin neutral buffersolution and decalcified in 10% ethylenediaminetetraacetic
acid (EDTA). The specimens were then dehydrated
through a series of graded ethanol, infiltrated and em-
bedded in paraffin wax. The tissues were cut into 6 μm
sections and stained with hematoxylin and eosin (H & E).
The sections were observed and photographed with a
microscope (TY9648; Leica).
For immunohistochemical staining, paraffin-embedded
sections were deparaffinized, hydrated and incubated
with 3% hydrogen peroxide, and then boiled in sodium
citrate buffer for 10 minutes. After the sections were
cooled at room temperature, the slides were blocked for
30 minutes with 1.5% horse serum. Subsequently, the
slides were incubated with the primary BMP2 antibody
(Abcam, ab6285, 1:200 dilution) or collagen I (Col I)
(Sigma, C2456, 1:1000 dilution) overnight at 4°C. Next,
the slides were incubated with biotinylated secondary
antibody for 30 minutes at room temperature. Counter-
staining was performed with hematoxylin. The slides were
observed by three individuals who were blinded to the
treatments.
To confirm the implantation of the transfected USCs
in the β-TCP scaffold and their survival, sections were
analyzed with a fluorescence microscope (Nikon, ECLIPSE,
Ti). Briefly, the sections were treated with 0.2% Triton
X-100 for 20 minutes. After washing, the sections were
blocked with 5% normal goat serum in PBS for 30 minutes
at room temperature. The sections were washed three
times with PBS, and then incubated with the primary anti-
body OCN (Abcam, ab13420, 1:200 dilution) at 4°C over-
night, followed by incubation with Alexa Fluor 594 goat
anti-mouse secondary antibody (Invitrogen, 1:200) for
two hours. The sections were then stained with DAPI,
and the slides were observed under a fluorescence micro-
scope (MZFL III; Leica).
Statistical analysis
All quantitative data were expressed as means ± standard
deviations. Statistical analysis was performed via one-
way analysis of variance (ANOVA) using SPSS software




USCs were isolated successfully from voided urine. The
number of live cells in urine samples was 4.5 × 103/100 ml
urine (range 3.2 to 8.5 × 103). Most living cells in these
samples did not attach to culture plates and were dis-
carded when the culture media was replaced. Generally,
100 ml urine contained 1 to 2 progenitor cells. They
showed a fibroblastic morphology (Figure 1a), which is a
similar finding as those of our previous results. USCs can
be induced to differentiate into osteoblast and adipocyte
Figure 1 Characterization of human urine-derived stem cells. (a) Phase-contrast microscopy of USCs in primary culture. (b) Alizarin Red S
staining showing the osteogenic differentiation of USCs. (c) Oil red O staining showing the adipogenic differentiation of USCs. (d). Flow cytometry
analysis of the expression of USCs surface markers. Scale bars = 100 μm. USCs, urine-derived stem cells.
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differentiation (Figure 1b). Oil Red O staining showed the
lipid vesicles in cytoplasm of USCs, which demonstrated
the adipogenic differentiation (Figure 1c).
The immunophenotypes of the USCs are shown in
Figure 1d. USCs positively expressed CD29, CD44, CD73
and CD90. However, they were negative for CD34, CD45,
CD133 and HLA-DR.
Transduction conditions and efficiency
The Lentiviral-BMP2 transduction conditions were opti-
mized by considering both transduction efficiency and cell
viability. As expected, the percentage of GFP-positive cells
increased with the increased MOI (Figure 2a, b, and c).
Transduction efficiency was further evaluated by flowcytometry three days after transduction. As shown in
Table 2, the percentage of GFP-positive cells increased as
the MOI increased.
To determine the viability of USCs following Lentiviral
gene transduction, CCK-8 analysis was performed. Figure 2d
shows that Lentiviral-GFP and Lentiviral-BMP2 transduc-
tion had no significant effect on cell viability. We concluded
that the optimized Lentiviral-BMP2 transduction MOI was
100 because it resulted in the highest GFP-positive rate and
had no significant effect on cell viability. All of our follow-
ing experiments were performed at an MOI of 100.
Expression of BMP2 gene and protein
To examine the expression of BMP2 in Lentiviral-BMP2
transduced USCs, cells were harvested and analyzed by
Figure 2 Lentiviral-BMP2 transduced USCs and the effect of transduction on USCs proliferation and BMP2 gene and protein expression.
USCs with Lentiviral-BMP2 vectors at different MOIs (a:10; b:50; c:100). Cells were assessed for the presence of positive GFP fluorescence
microscopy three days after transduction. Scale bar = 250 μm. (d) Cell proliferation assays were performed at 1, 3 and 7 days post-transduction. The
means and standard deviations were calculated from three experiments. (e) RT-PCR analysis showed that the transduced USCs highly expressed
the BMP2 gene at days 3, 7 and 14 after transduction. (f) ELISA results indicated that BMP2 production in Lentiviral-BMP2 transduced USCs was
significantly increased as compared to that in Lentiviral-GFP transduced USCs or normal USCs. #, P <0.01 (compared with normal USCs)
and *, P <0.01 (compared with Lentiviral-GFP transduced USCs). BMP2, bone morphogenic proteins 2; MOI, multiplicity of infection;
USCs, urine-derived stem cells.
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pacted the amount of BMP2 gene expression (Figure 2e).
The results demonstrated the stable expression of BMP2
in Lentiviral-BMP2 transduced USCs. The amount of
BMP2 protein secreted by these transduced cells was
quantified using an ELISA assay kit (Figure 2f ). The
mean secretion of BMP2 over 4, 7, 10 and 14 days was
40.5 ± 21.5, 108.1 ± 31.2, 87.4 ± 21.5 and 99.7 ± 28.7 ng/
mg protein/day in Lentirival-BMP2 transduced USCs,
respectively.Table 2 The percentage of GFP-positive cells at different
MOI
MOI Samples number Positive rate
10 3 30 ± 6%
50 3 53 ± 4%
100 3 90 ± 7%
MOI, multiplicity of infection.In vitro osteogenic induction
ALP activity assay and mineral calcium staining
We assessed osteogenic differentiation by measuring
ALP activity and mineralization. As shown in Figure 3a,
the ALP activity of the Lentiviral-BMP2 transduced
USCs increased gradually over 14 days of cell culture
and was significantly higher than that of the normal
USCs and Lentiviral-GFP transduced USCs (P <0.05).
Fourteen days after transduction, Alizarin Red S and
von Kossa staining showed that the mineralized nodules
were significantly greater in Lentiviral-BMP2 transduced
USCs than in normal USCs and Lentiviral-GFP trans-
duced USCs (Figure 3b,c,d,e, f and g). Taken together,
these results demonstrate that Lentiviral-BMP2 trans-
duction enhances the osteogenic activity of USCs.
Expression of osteogenic related marker OCN and Runx2
Expression of Runx2 and OCN genes in Lentiviral-
BMP2 transduced USCs was detected by RT-PCR on
days 3, 7 and 14. Transcription level of these genes was
Figure 3 In vitro osteogenic differentiation of lentivirus-transduced USCs. (a) ALP activity in Lentiviral-BMP2 transduced USCs was significantly
higher than that in Lentiviral-GFP transduced USCs and normal USCs. The deposited calcium was detected using Alizarin Red S (b, d and d) and von
Kossa staining (e, f and g) at 14 days after transduction. (b and e) Normal USCs. (c and f) Lentiviral-GFP transduced USCs. (d and g) Lentiviral-BMP2
transduced USCs. For Alizarin Red S staining, the red color indicates calcium deposition (d); for von Kossa staining, dark patches indicate calcium
deposition (g). Scale bar = 100 μm. #, P <0.05 (compared with normal USCs) and *, P <0.05 (compared with Lentiviral-GFP transduced USCs).
ALP, alkaline phosphatase; BMP2, bone morphogenic proteins 2; USCs, urine-derived stem cells.
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than in normal USCs or Lentiviral-GFP transduced
USCs (Figure 4a). To further detect the osteogenic differ-
entiation of Lentiviral-BMP2 transduced USCs resulting
from gene transduction, we used immunofluorescence to
analyze the osteogenic-related proteins Runx2 and OCN.
The results showed that Runx2 and OCN were expressed
in Lentiviral-BMP2 transduced USCs at 7 and 21 days
after transduction (Figure 4b), respectively. We conclude
that the transduction of Lentiviral-BMP2 enhances the
osteogenic differentiation of USCs in vitro.
In vivo bone formation
To further test the osteogenic potential of Lentiviral-BMP2
transduced USCs in vivo, Lentiviral-BMP2 transduced
USCs were seeded on β-TCP scaffolds and transplanted
into the hind limbs of nude mice. Six weeks after in vivo
implantation, mice were sacrificed and samples werecollected and examined. H & E staining revealed that
Lentiviral-BMP2 transduced USCs generated bone tissues,
whereas little ectopic bone formation was observed in
control mice implanted with normal USCs (Figure 5a and b).
The results showed Lentiviral-BMP2 transduction dramat-
ically increased USCs osteogenic activity relative to USCs
control in vivo.
Immunohistochemistry targeting BMP2 and Collagen I
(Col I) was performed. It revealed the negative staining
of BMP2 and Col I in the USCs transplantation group
(Figure 6a and c). However, positive immunohistochemi-
cal staining for BMP2 and Col I was observed in the
Lentiviral-BMP2 transduced USCs transplantation group
(Figure 6b and d).
OCN immunofluorescence was performed to determine
the osteogenic differentiation of USCs with or without
Lentiviral-BMP2 transduction. Human derived OCN
stained in red in the Lentiviral-BMP2 transduction
Figure 4 Gene and protein expression of bone related factors in transduced and normal USCs. (a) The mRNA expression level of Runx2
and OCN at day 3, 7 and 14 after transduction. (b) The protein expression of Runx2 and OCN was detected with immunofluorescence. Blue: DAPI;
red: Runx2 or OCN. BMP2 gene transduction significantly increased the protein expression of Runx2 and OCN. Scale bar = 50 μm. #, P <0.05
(compared with normal USCs) and *, P <0.05 (compared with Lentiviral-GFP transduced USCs). BMP2, bone morphogenic proteins 2; DAPI,
4',6-diamidino-2-phenylindole; OCN, osteocalcin; Runx2, Runt-related protein-2; USCs, urine-derived stem cells.
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was detected in the normal USCs transplantation group
(Figure 7a). This result indicated that Lentiviral-BMP2
transduced USCs were positive for the osteoblast marker
OCN, which suggested that Lentiviral-BMP2 transduced
USCs differentiate into osteoblasts in response to the
secreted BMP2.Figure 5 H & E staining of histological sections formed by the implan
into the hind limb of athymic mice for six weeks. (a) The USCs/β-TCP i
USCs/β-TCP resulted in bone formation in the outer surface and inner pore
NB: new bone; CA: cartilage tissue. Β-TCP, β-tricalcium phosphate; BMP2, boDiscussion
In the present study, we demonstrated that the osteogenic
activity of USCs can be enhanced by the gene transduction
of Lentiviral-BMP2. After ex vivo transduction, Lentiviral-
BMP2 transduced USCs can secrete high levels of BMP2
and induce de novo bone formation in vivo. To the best of
our knowledge, this study is the first to evaluate thetation of Lentiviral-BMP2 transduced USCs/β-TCP and USCs/β-TCP
nduced no bone formation, whereas the Lentiviral-BMP2 transduced
of the implants (b). Scale bar = 50 μm. TCP: β-TCP; FB: fibroblast tissue;
ne morphogenic proteins 2; USCs, urine-derived stem cells.
Figure 6 Immunohistochemical staining of BMP2 and Collagen I of the transplanted scaffold at six weeks post-implantation. (a) BMP2
and (c) Collagen I staining in the normal USCs transplantation group. (b) BMP2 and (d) Collagen I staining in the Lentiviral-BMP2 transplantation
group. The arrows indicate the positive staining of BMP2 or Collagen I in the Lentiviral-BMP2 transplantation group. Scale bar for a and c = 50 μm;
b and d = 100 μm. BMP2, bone morphogenic proteins 2; USCs, urine-derived stem cells.
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of gene transduction on their osteogenic ability.
USCs are adult stem cells that have been characterized
in recent years [1]. USCs have the capacity to differentiate
into osteoblasts, chondrocytes, adipocytes, muscle and
neurons. The large source for the cells and non-invasive
method required to collect them has made USCs a suitableFigure 7 Human derived OCN was detected by immunostaining after
The arrows indicate the positive staining of OCN. Scale bar = 100 μm. Β-TC
osteocalcin; USCs, urine-derived stem cells.choice for tissue engineering, including bone tissue en-
gineering. The bone marrow is regarded as the natural
reservoir of osteoprogenitor cells, and bone marrow-
derived mesenchymal stem cells (BM-MSCs) are widely
used to deliver growth factors for bone regeneration
[10-12]. Nevertheless, bone marrow aspiration requires
invasive surgery and causes additional pain to patients;six weeks. (a) USCs/β-TCP; (b) Lentiviral-BMP2 transduced USCs/β-TCP.
P, β-tricalcium phosphate; BMP2, bone morphogenic proteins 2; OCN,
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bone marrow for these applications. Therefore, cell sources
that are easily accessible and relatively abundant have a pri-
ority for cytotherapy. Due to their non-invasive procure-
ment method and their high self-renewal capacity, USCs
have gained increasing attention.
In the current study, we used culture media free of
fetal bovine serum. Previous studies have demonstrated
that various in the serum composition [13]. Additionally,
the use of animal products has a high risk of virus trans-
mission [14]. Currently, the serum-free media we used is
mainly supplemented with approximately essential com-
ponents including: insulin transferrin and selenium (ITS
supplement), transferrin, glucocorticoids, triiodothyron-
ine (T3), fibroblast growth factor-2 and glutamine. We
combined these supplement depend on the healthy ex-
pansion of mesenchymal stem cells and the source envir-
onment of USCs [15]. The fetal bovine serum free media
pave the way for clinical application of USCs.
Stem cell-based gene therapy is a promising tool to
enhance bone repair. Substantial studies have demon-
strated that BMP2 gene transduction can be used to en-
hance the bone formation ability of stem cells [7,16,17].
Our goal is to utilize BMP2 gene transduction to pro-
mote the osteogenic potential of USCs. We integrated
the BMP2 gene into lentiviral vectors and transduced
them into USCs with an MOI of 10, 50 and 100. The re-
sults showed that at an MOI of 100, over 90% of the
USCs were transduced, which indicates a high transduc-
tion efficiency. In addition, the transduction process was
found to have no significant effect on cell viability.
After in vitro transduction, USCs expressed high levels
of the BMP2 gene and secreted a large amount of BMP2
protein. Furthermore, we present evidence that the se-
creted BMP2 promoted USCs differentiation into osteo-
blasts. ALP activity and mineral calcium deposition is a
useful marker for osteogenic differentiation. Only osteo-
blasts or cells with osteoblastic characteristics produce
OCN [18]. ALP activity and mineral calcium deposition
increased significantly after transduction with Lentiviral-
BMP2. Lentiviral-BMP2 transduction also stimulated the
gene and protein expression of Runx2 and OCN. These
data showed that the BMP2 production was sufficient to
lead to robust osteogenesis by USCs. Previous studies
have demonstrated that BMP2 secreted by transduced
cells can initiate a physiological effect on stem cells [12].
As expected, the transduction of the BMP2 significantly
enhanced the osteogenic differentiation of USCs in vitro.
We investigated whether Lentiviral-BMP2 transduced
USCs combined with porous ceramic scaffolds made of
β-TCP could induce ectopic bone formation in vivo.
When scaffolds were seeded with Lentiviral-BMP2 trans-
duced USCs, bone was observed six weeks after implant-
ation. The control scaffold with USCs failed to formbone, indicating the crucial role of the Lentiviral-BMP2
transduced USCs during bone formation. In fact, previ-
ous studies have demonstrated that BMP2 can enhance
the ectopic bone formation of bone marrow-derived
MSCs [19]. However, the fate of transplanted stem cells
in vivo differed according to previous studies. Quintavalla
et al. reported the extensive loss of implanted MSCs on
days 7 and 14 in osteochondral defects in goat [20].
Hasegawa et al. detected transplanted MSCs four weeks
after implantation within the regenerated tissues [21].
In this study, we evaluated the survival of the trans-
planted cells. The identification of human-derived OCN
within the scaffold indicated that some of the trans-
planted cells survived. We demonstrated that the trans-
planted cells had survived at six weeks and exerted their
osteogenic stimulus on the implantation site to form
bone.
Viral vectors currently represent the most efficient
approach for gene delivery [22]. A number of viral con-
structs have been investigated for gene delivery, with
the most common including adenovirus, retrovirus,
lentivirus and adeno-associated virus [23]. Lentiviral
vectors facilitate long-term target gene expression and
are attractive with regard to gene therapy [24]. In
addition, the immunogenicity associated with Lenti-
viral vectors is low. How to resolve the safety concerns
about Lentiviral vectors is critical for their translation
into clinical therapy. Several methods have been pro-
posed to enhance the safety of Lentiviral vectors for
gene transduction [25-27]. The results are encouraging
and motivate further research to better apply Lentiviral
vectors.
Conclusions
Our study shows that the osteogenic potential of USCs
can be significantly enhanced by BMP2 gene transduction.
These transfected cells can undergo in vitro osteogenic
differentiation without osteogenic medium. In vivo bone
formation assays showed that the Lentiviral-BMP2 trans-
duced USCs provide sufficient stimuli for bone formation.
We conclude that the use of BMP2 gene therapy is a use-
ful means of enhancing the osteogenic activity of USCs
both in vitro and in vivo. These results provide a novel
strategy for enhancing the osteoproductive ability of
USCs.
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